Details

Autor(en) / Beteiligte

• Tenforde, Mark W
• Weber, Zachary A
• Yang, Duck-Hye
• DeSilva, Malini B
• Dascomb, Kristin
• Irving, Stephanie A
• Naleway, Allison L
• Gaglani, Manjusha
• Fireman, Bruce
• Lewis, Ned
• Zerbo, Ousseny
• Goddard, Kristin
• Timbol, Julius
• Hansen, John R
• Grisel, Nancy
• Arndorfer, Julie
• McEvoy, Charlene E
• Essien, Inih J
• Rao, Suchitra
• Grannis, Shaun J
• Kharbanda, Anupam B
• Natarajan, Karthik
• Ong, Toan C
• Embi, Peter J
• Ball, Sarah W
• Dunne, Margaret M
• Kirshner, Lindsey
• Wiegand, Ryan E
• Dickerson, Monica
• Patel, Palak
• Ray, Caitlin
• Flannery, Brendan
• Garg, Shikha
• Adams, Katherine
• Klein, Nicola P

Titel

Influenza Vaccine Effectiveness Against Influenza A–Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022–2023

Ist Teil von

• The Journal of infectious diseases, 2023-12

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Background The 2022–2023 United States influenza season had unusually early influenza activity with high hospitalization rates. Vaccine-matched A(H3N2) viruses predominated, with lower levels of A(H1N1)pdm09 activity also observed. Methods Using the test-negative design, we evaluated influenza vaccine effectiveness (VE) during the 2022–2023 season against influenza A–associated emergency department/urgent care (ED/UC) visits and hospitalizations from October 2022 to March 2023 among adults (aged ≥18 years) with acute respiratory illness (ARI). VE was estimated by comparing odds of seasonal influenza vaccination among case-patients (influenza A test positive by molecular assay) and controls (influenza test negative), applying inverse-propensity-to-be-vaccinated weights. Results The analysis included 85 389 ED/UC ARI encounters (17.0% influenza A positive; 37.8% vaccinated overall) and 19 751 hospitalizations (9.5% influenza A positive; 52.8% vaccinated overall). VE against influenza A–associated ED/UC encounters was 44% (95% confidence interval [CI], 40%–47%) overall and 45% and 41% among adults aged 18–64 and ≥65 years, respectively. VE against influenza A–associated hospitalizations was 35% (95% CI, 27%–43%) overall and 23% and 41% among adults aged 18–64 and ≥65 years, respectively. Conclusions VE was moderate during the 2022–2023 influenza season, a season characterized with increased burden of influenza and co-circulation with other respiratory viruses. Vaccination is likely to substantially reduce morbidity, mortality, and strain on healthcare resources.